Seock-Ah Im

62PUBLICATIONS
396CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Ngā pūtaiao koiora-hauora, haumanu hoki o te Māori (Māori biomedical and clinical sciences)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (62)

|Oct 06, 2026
Body Composition Changes Induced by Perioperative Chemotherapy in Patients With Breast Cancer.

|Oct 06, 2026
Poly(ADP-ribose) Polymerase Inhibitor Talazoparib Inhibits DNA Damage Repair in Breast Cancer Cell Lines With or Without BRCA1/2 Mutation.

|Sep 30, 2026
Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.

|Sep 24, 2026
Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.

|Sep 21, 2026
Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

|Jun 08, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Pageof 11

Frequent Collaborators

13 joint publications

Kyung-Hun Lee

8 joint publications

Nadia Harbeck

8 joint publications

Hope S Rugo

7 joint publications

Tae-Yong Kim